BioSpace News Archive

FDA

InvaGen Receives FDA Approval for Generic of Pfizer’s Lyrica

The drug is approved for use for management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, adjunctive therapy for partial-onset seizures in patients 17 years of age and older, fibromyalgia, and neuropathic pain associated with spinal cord injury.

July 22, 2019
·
3 min read
·
Mark Terry
Drug Development

Subcutaneous Formulation of Takeda’s Entyvio Hits the Mark in Crohn’s Trial

Takeda will release complete Phase III data at a future scientific conference and is planning on seeking regulatory approval for the investigational formulation.

July 22, 2019
·
2 min read
·
Alex Keown
Business

DURECT and Gilead Collaborate on HIV Therapy in Potential $320 Million+ Deal

“We are pleased to be working on this program with Gilead given their expertise and global leadership in the HIV and HBV fields,” stated James E. Brown, president and chief executive officer of DURECT.

July 22, 2019
·
3 min read
·
Mark Terry
FDA

Baxter International Nabs FDA Approval for Insulin IV Infusion

Myxredlin is intended for use only in acute care settings under medical supervision.

July 22, 2019
·
2 min read
·
Alex Keown
18th Hospital Management Asia to be held in Hanoi on 11-12 September

Hospital Management Asia 2019, the annual event for Asian healthcare leaders, will be held September 11-12, 2019, at the National Convention Centre of Vietnam.

July 22, 2019
·
4 min read
DNA Microscopy Changes the Way Scientists Analyze DNA

A new technique, DNA microscopy, is allowing scientists to visualize DNA in a way not previously possible. And there isn’t even an actual microscope involved.

July 22, 2019
·
3 min read
·
Gaius J. Augustus, PhD
Congenica simplifies software branding and enhances platform with CNV calling to deliver genomic medicine globally

Congenica, a digital health company enabling accelerated genomic data interpretation, today announced it has renamed its software platformCongenica® and expanded its capabilities to include CNV calling for exome and gene panel sequencing.

July 22, 2019
·
6 min read
Policy

NUMAFERM closes licensing agreement with PEPDesign

Low cost production and superior product purity of the diabetes drug liraglutide with NUMAFERM’s unique technology platform

July 22, 2019
·
4 min read
Combined online self-management for pain, associated anxiety and depression works

Online self-management helps; for some the online system plus nurse telecare helps more

July 22, 2019
·
4 min read
Drug Development

Achillion’s ACH-5228 Achieves Positive Results In Phase 1 Multiple Ascending Dose Study In Healthy Volunteers

Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, announced results from their Phase 1 multiple ascending dose study with ACH-5228 outside of the United States.

July 22, 2019
·
7 min read